Breaking News, Collaborations & Alliances

TriLink to Supply CleanCap Technology to Lonza

Will offer its patented cap analogs for use in Lonza’s global mRNA development and manufacturing services.

Author Image

By: Charlie Sternberg

Associate Editor

TriLink BioTechnologies, a Maravai LifeSciences company and global provider of life science reagents and services, has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, that aims to drive greater access to CleanCap mRNA capping technologies as the demand for mRNA continues to grow.   Per the terms of the agreement, TriLink will supply its patented CleanCap M6, CleanCap AG 3’OMe, CleanC...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters